Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors.

about

External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies.

P2860

Q53695831-634FACB7-E870-46FC-A016-BC38B7F1A0E1

P2860

Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors.

Item

http://www.wikidata.org/entity/Q53092330

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Radiation safety of outpatient ...... rapy of neuroendocrine tumors.

@en

Radiation safety of outpatient ...... rapy of neuroendocrine tumors.

@nl

type

Item

label

Radiation safety of outpatient ...... rapy of neuroendocrine tumors.

@en

Radiation safety of outpatient ...... rapy of neuroendocrine tumors.

@nl

prefLabel

Radiation safety of outpatient ...... rapy of neuroendocrine tumors.

@en

Radiation safety of outpatient ...... rapy of neuroendocrine tumors.

@nl

P1476

Radiation safety of outpatient ...... rapy of neuroendocrine tumors.

@en

P2093

J Harvey Turner

http://www.w3.org/2001/XMLSchema#string

Phillipe J Calais

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

Outpatient therapeutic nuclear oncology.

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.

Radioactive iodine (131I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective.

Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms.

A survey of guidelines in 27 EANM associated societies by the EANM Task Group on Quality Assurance and Standardisation. European Association of Nuclear Medicine.

P2888

s12149-014-0843-8

P304

531-539

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12149-014-0843-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24687907

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors.

about

P2860

P2860

Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921